Injection of denosumab-mobz biosimilar (Oziltus), billed per 1 milligram administered

Denosumab-mobz (brand name Oziltus) is a biosimilar to the reference product denosumab (Prolia/Xgeva), a RANK ligand inhibitor that reduces osteoclast-mediated bone resorption. This code is billed per 1 mg, so units must reflect the total dose administered. It is used for conditions involving pathologic bone loss or hypercalcemia of malignancy depending on the dosing regimen.

This code applies when the biosimilar denosumab-mobz is dispensed and administered in a clinical setting for indications such as postmenopausal osteoporosis, bone loss associated with hormone ablation therapy, or prevention of skeletal-related events in patients with bone metastases. Documentation should confirm the specific product name (Oziltus), lot number, dose in mg, route of administration (subcutaneous injection), and the clinical indication. Payer prior authorization records and the prescribing order should align with the documented diagnosis.

• Units are critical: Prolia dosing is 60 mg (bill 60 units); Xgeva dosing is 120 mg or 120 mg monthly/quarterly — verify the exact dose administered and bill accordingly, as undercoding or overcoding units is a common audit trigger.
• Do not interchange with reference product codes: This biosimilar has its own distinct HCPCS code separate from denosumab (Prolia: J0897; Xgeva: J0895) — substituting codes based on the originator product is incorrect even if therapeutically equivalent.
• Biosimilar modifier requirements: Some payers require modifier BP (beneficiary elected biosimilar) or BR (beneficiary elected reference product) for Medicare claims — confirm payer-specific billing rules before submission.